SMA Newsroom

Mar 25, 2026

Community update Roche: Discontinuation of emugrobart for SMA

We regret to inform that Roche has decided not to advance emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for SMA, leading to the discontinuation of the MANATEE clinical study.

TreatmentsJan 13, 2026

High-Dose Regimen of nusinersen receives European Commission Approval for the treatment of SMA

High-Dose Regimen of nusinersen receives European Commission Approval for the treatment of SMA.
TreatmentsNov 25, 2025

Breaking news: FDA approval for Itvisma® (onasemnogene abeparvovec-brve), the intrathecal formulation of onasemnogene abeparvovec.

Today, Novartis announced that the company has received the FDA approval for Itvisma® (onasemnogene abeparvovec-brve), the intrathecal formulation of onasemnogene abeparvovec, to treat SMA in adult and pediatric patients 2 years of age and older with a confirmed mutation in SMN1.

 

ResearchClinical Trials initiativesClinical trialsTherapy & CareNov 20, 2025

EUPESMA 2023 Survey Results

We’re thrilled to share the latest publication in SMA Europe’s One Goal editorial series!